Real-World Estimates of Adrenal Insufficiency–Related Adverse Events in Children With Congenital Adrenal Hyperplasia

Salma R. Ali,1,2 Jillian Bryce,2 Houra Haghpanahan,3 James D. Lewsey,3 Li En Tan,1 Navoda Atapattu,4 Niels H. Birkebaek,5 Oliver Blankenstein,6 Uta Neumann,6 Antonio Balsamo,7 Rita Ortolano,7 Walter Bonfig,8 Hedi L. Claahsen-van der Grinten,9 Martine Cools,10 Eduardo Correa Costa,11 Feyza Darendeliler,12 Sukran Poyrazoglu,12 Heba Elsedfy,13 Martijn J.J Finken,14 Christa E. Fluck,15 Evelien Gevers,16 Mártia Korbonits,16 Guilherme Guaragna-Filho,17 Tulay Guran,18 Ayla Guven,19 Sabine E. Hannema,20,21 Claire Higham,22 Ieuan A. Hughes,23 Rieko Tadokoro-Cuccaro,23 Ajay Thankamony,23 Violeta Iotova,24 Nils P. Krone,25 Ruth Krone,26 Corina Lichiardopol,27 Andrea Luczay,28 Berenice B. Mendonca,29 Tania A.S.S. Bacheqa,29 Mirela C. Miranda,29 Tatjana Milenkovic,30 Klaus Mohrike,31 Anna Nordenstrom,32 Silvia Einaudi,33 Hetty van der Kamp,34 Ana Vieites,35 Liat de Vries,36,37 Richard J. M. Ross,25 and S. Faisal Ahmed1,2

1Developmental Endocrinology Research Group, School of Medicine, Dentistry & Nursing, University of Glasgow, Glasgow G51 4TF, UK; 2Office for Rare Conditions, Royal Hospital for Children & Queen Elizabeth University Hospital, Glasgow G51 4TF, UK; 3Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow G12 8RZ, UK; 4Lady Ridgeway Hospital, Colombo 00800, Sri Lanka; 5Department of Paediatrics, Aarhus University Hospital, Aarhus DK-8200, Denmark; 6Centre for Chronic Sick Children, Institute for Experimental Paediatric Endocrinology, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany; 7Department of Medical and Surgical Sciences, Pediatric Unit, Center for Rare Endocrine Conditions (Eno-ERN), S.Orsola-Malpighi University Hospital, 40138 Bologna, Italy; 8Department of Paediatrics, Technical University München, D-80804 Munich, Germany and and Department of Paediatrics, Klinikum Wels-Grieskirchen, A-4600 Wels, Austria; 9Department of Paediatric Endocrinology, Amalia Childrens Hospital, Radboud University Medical Centre, 6525 GA Nijmegen, Netherlands; 10University Hospital Ghent, Ghent University, 9000 Ghent, Belgium; 11Pediatric Surgery Service, Hospital de Clínicas de Porto Alegre, UFRGS, Porto Alegre - RS, 90035-903, Brazil; 12Istanbul Faculty of Medicine, Department of Paediatrics, Paediatric Endocrinology Unit, Istanbul University, Çapa 34093, Istanbul, Turkey; 13Department of Pediatrics, Ain Shams University, 11566, Cairo, Egypt; 14Emma Children’s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Endocrinology, 1105 AZ Amsterdam, The Netherlands; 15Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics and Department of BioMedical Research, Bern University Hospital Inselspital, University of Bern, 3010 Bern, Switzerland; 16Department of Endocrinology, William Harvey Research Institute, Barts and the London
Abstract

Background Although congenital adrenal hyperplasia (CAH) is known to be associated with adrenal crises (AC), its association with patient- or clinician-reported sick day episodes (SDE) is less clear.

Methods Data on children with classic 21-hydroxylase deficiency CAH from 34 centers in 18 countries, of which 7 were Low or Middle Income Countries (LMIC) and 11 were High Income (HIC), were collected from the International CAH Registry and analyzed to examine the clinical factors associated with SDE and AC.

Results A total of 518 children— with a median of 11 children (range 1, 53) per center— had 5388 visits evaluated over a total of 2300 patient-years. The median number of AC and SDE per patient-year per center was 0 (0, 3) and 0.4 (0.0, 13.3), respectively. Of the 1544 SDE, an AC was reported in 62 (4%), with no fatalities. Infectious illness was the most frequent precipitating event, reported in 1105 (72%) and 29 (47%) of SDE and AC, respectively. On comparing cases from LMIC and HIC, the median SDE per patient-year was 0.75 (0, 13.3) vs 0.11 (0, 12.0) ($P$ < 0.001), respectively, and the median AC per patient-year was 0 (0, 2.2) vs 0 (0, 3.0) ($P$ = 0.43), respectively.

Conclusions The real-world data that are collected within the I-CAH Registry show wide variability in the reported occurrence of adrenal insufficiency–related adverse events. As
Congenital adrenal hyperplasia (CAH) is an autosomal recessive condition with an incidence of approximately 1 in 15,000 and is most commonly due to 21-hydroxylase deficiency (1). In this form of CAH, a variable abnormality in steroidogenesis can result in varying levels of glucocorticoid (GC) and mineralocorticoid deficiency and in its most severe form, classic CAH, the patient may have severe primary adrenal insufficiency (2). CAH is the commonest cause of primary adrenal insufficiency in childhood (3), with a lifelong requirement for GC replacement and in most patients also mineralocorticoid replacement. Although GC treatment has improved survival in those with adrenal insufficiency (4), the risk of acute adrenal insufficiency, also known as an adrenal crisis (AC) has not been eliminated, with life expectancy remaining less than that of the general population (5, 6). An AC is usually associated with hospitalization, but the incidence of AC is very variable, with rates of between 5.2 and 10.9 per 100 person-years recently reported in children with CAH (7-10). It is possible that some of this variation is related to lack of a universally accepted definition of AC as well as its prodrome, often referred to as a sick day episode (SDE) (11, 12); it is also possible that there may be other factors that influence this variation, some that are patient-dependent and some that reflect on health care delivery (13). Nevertheless, there is increasing consensus that the avoidance of acute adverse events due to adrenal insufficiency is one of the most important outcomes that can be routinely measured (14, 15).

Given the rarity of CAH as well as AC in children, knowledge on the epidemiology of acute adrenal insufficiency–related adverse events, including SDE, in CAH is limited (7-10, 16, 17), with a paucity of data in large, multicenter, international cohorts. The International Congenital Adrenal Hyperplasia Registry (I-CAH) represents a valuable resource for evaluating outcomes in this rare condition (18). In this study, using data from the I-CAH Registry, we sought to investigate the occurrence of adverse events, including SDE and AC, in children with classic 21-hydroxylase deficiency CAH and examine the association of these outcomes with clinical variables.

**Methods**

**Study population**

All patients under the age of 18 years who were registered as having 21-hydroxylase deficiency CAH were identified from the I-CAH Registry (https://home.i-cah.org/) in July 2019. The I-CAH Registry is an international database of pseudonymized information on patients with CAH and is approved by the National Research Ethics Service in the United Kingdom as a research database of information that is collected as part of routine clinical care (18). The data within the registry are deposited by clinicians following informed consent from patients or guardians. Only those cases of 21-hydroxylase deficiency on GC with or without mineralocorticoid (fludrocortisone [FC]) were included. For the purpose of this study, the phenotypic classification into salt-wasting and simple virilizing CAH was based on concurrent treatment with FC.

**Clinical data collection**

The I-CAH Registry collects data on acute adrenal insufficiency–related adverse events since a patient’s last clinic visit. Clinicians with cases meeting the inclusion criteria were approached to enter data for a minimum of 2 clinic visits per patient per year. SDE and AC were based on the clinical judgment of the reporting clinician. For each SDE, data were available on: the duration of SDE (number of days); any predisposing condition at the time of SDE (infectious illness, surgery, other, not known); management of each SDE, including sick day management of oral steroids (doubled, >doubled, not increased, not known) and the requirement for intramuscular hydrocortisone (HC) injection (yes, no, not known); the occurrence of AC (yes, no, not known); the need for health professional input (self-managed at home, health professional only, emergency room, admission to hospital, intensive care unit). Data were also gathered about GC and FC regimens (preparation, dose, frequency) at the time of clinic visits. HC-equivalent dose (ED) was calculated by multiplying prednisolone dose by 5 or dexamethasone dose by 80 (19, 20). Total GC dose (HC-equivalent) was converted from mg to mg per m2 using the Mosteller formula for calculation of body surface area (BSA) (21), or using predefined BSA values for weight as outlined in the British National Formulary for Children (22). GC and FC doses were categorized as low, normal, or high, based on the Endocrine Society clinical practice guidance for 21-hydroxylase deficiency CAH (2018) (1) as follows: GC low <10 mg/m2/day, normal 10 to 15 mg/m2/day, high >15 mg/m2/day; FC low <50 µg/day, normal 50 to 200 µg/day, high >200 µg/day.
Statistical analysis

A longitudinal analysis of repeated measures reported from multiple visits was performed. The main outcome measures were occurrence of SDE, an increase in sick day oral GC dose, HC injection, AC, and hospitalization defined as attendance at the emergency room or admission to hospital. Multilevel logistic regressions were applied to examine the association of these outcome measures with clinical data obtained at each visit including age, sex, phenotype, GC, and FC dose. Accordingly, a 2-level multilevel regression model was built with individual patients (level 1) nested within centers (level 2). Random (intercept) effects for both levels were included in the modeling to allow variations between individuals and centers to be accounted for. The observed frequency of SDE and AC was determined as incidence rate, calculated as the number of SDE and AC divided by person-years. For assessment of geographical differences in the occurrence of SDE and AC, participating countries were categorized as those from a low or middle income country (LMIC) or from a high income country (HIC) as defined by the 2019 World Bank classification (23). Inter-group comparison for these variables was performed by the Mann-Whitney U test. The Fisher Exact test was performed to compare proportions in different groups. Results are reported as frequencies and percentages, median (with ranges) or odds ratios (OR) and 95% confidence intervals (CI). Data analysis was performed using R statistical software version 3.5.3 and Minitab version 18 statistical software (Minitab LLC, State College, PA, USA).

Results

Case selection

At the time of the study, 1426 cases of CAH were registered in the I-CAH Registry. Data on clinic visits including adverse events were available for 518 children younger than 18 years with 21-hydroxylase deficiency CAH (Fig. 1). There was no significant difference in the proportion of cases from HIC or LMIC countries, CAH type, or sex assigned between those with and without clinic visits data (24). Of the 518 children, 275 (53%) were girls, 459 (89%) had salt-wasting CAH and 59 (11%) had simple virilizing CAH. These children were reported from 34 centers in 18 countries with a median of 11 cases per center (1, 53) and 316 (61%) were from a high-income country (HIC). A total of 5388 clinic visits, occurring between 1984 and 2019, were evaluated in the 518 children, comprising a total of 2300 patient-years (Table 1). The median duration of follow-up per patient was 3 years (0.1, 17.9), with a median of 2.9 visits (0.3, 25.7) per patient-year. The median patient age at the time of the visits was 2 years (0, 17.9).

Steroid replacement

Of the 5388 clinic visits, information on steroid replacement was available in 5250 visits (97%). Of the 518 children, 435 (84%) were receiving HC, with 19 (3.5%) and 7 (1.5%) receiving prednisolone and dexamethasone, respectively; 16 children (3%) were taking a combination of different types of GC. HC use was documented in 4733 visits (90%) and the median steroid replacement dose, as HC ED, was 12.5 mg/m²/day (2.3, 71.4). In the 4226 visits where GC doses were known, the GC doses were reported to be within the recommended HC ED of 10 to 15 mg/m²/day in 2019 visits (48%) (Table 1). Of the 518 children, 459 (89%) were receiving FC at the time of clinic visits, with a median dose of 93.8 µg/day (12.5, 500) and doses were reported to be within the recommended range of 50 to 200 µg/day in 4374 visits (90%) (Table 1).

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Participant selection from the I-CAH Registry. Abbreviations: 21-OHD, 21-hydroxylase deficiency; CAH, congenital adrenal hyperplasia; I-CAH, International Congenital Hyperplasia registry.
Occurrence of sick day episodes and adrenal crises

Of the 5388 visits in 518 children, a total of 1544 SDE were reported in 1089 visits (20%) from 334 children (64%), of whom 167 (50%) were female. Based on a total observation period of 2300 patient-years, the SDE incidence rate was calculated at 67 per 100 patient-years and the median duration of a SDE was 3 days (1, 41). Of the 1089 visits where a SDE was reported, in 989 (91%), the reported number of SDE since last clinic visit was ≤2. A median of 1 SDE (1, 8) was reported per patient per visit, and the median number of SDE per patient-year per center was 0.4 (0, 13.3) (Fig. 2). The median SDE per patient-year was 0.75 (0, 13.3) vs 0.11 (0, 12.0); P < 0.001, in HIC and LMIC countries, respectively. Of the 1544 SDE, 62 events (4%) were associated with an AC in 49 out of 334 children (15%), all of whom had salt-wasting CAH and of whom 22 (45%) were female. The overall median AC per patient-year was 3.9 per 100 patient-years, with an overall AC incidence rate of 2.7 per 100 patient-years for all children. On examining temporal trends, from 1980 to 2000, 12 AC were reported in association with 37 SDEs in a total of 6 patients; thus, 32% of SDEs were associated with an AC. For the same 20-year period after 2000, 50 AC were reported in 1507 SDEs in a total of 43 patients; thus, only 3% of SDEs were associated with an AC following the year 2000.

| Table 1. Characteristics of Children With 21-Hydroxylase Congenital Adrenal Hyperplasia, at Clinic Visits (n = 5388) |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Group           | Patients, n     | Total visits, n (%) | Visits per patient, median (range) | Total follow-up duration (years) | Follow-up per patient, median (range) | Total visits per patient-year | Visits per patient-year, median (range) |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Children, <18 y | 518             | 5388 (total)    | 9 (1, 42)       | 2300            | 3.0 (0.1, 17.9) | 1744            | 2.9 (0.3, 25.7) |
| Sex             |                 |                 |                 |                 |                 |                 |                 |
| F               | 275             | 2821 (52.4)     | 9 (1, 35)       | 1277            | 3.0 (0.1, 17.9) | 881             | 2.9 (0.3, 18.2) |
| M               | 243             | 2567 (47.6)     | 9 (1, 42)       | 1003            | 3.0 (0.2, 17.9) | 863             | 3.0 (0.4, 25.7) |
| CAH phenotype   |                 |                 |                 |                 |                 |                 |                 |
| SW              | 459             | 5086 (94.4)     | 9 (1, 42)       | 1984            | 3.0 (0.1, 17.9) | 1549            | 3.0 (0.3, 25.7) |
| SV              | 59              | 302 (5.6)       | 9 (1, 35)       | 296             | 3.0 (0.2, 17.9) | 195             | 2.5 (0.5, 14.7) |
| Age at visit, y |                 |                 |                 |                 |                 |                 |                 |
| <1              | 418             | 1621 (30.1)     | 3 (1, 16)       | 234             | 0.7 (0.0,1.0)   | 2770            | 5.9 (2.3, 51.4) |
| 1–4.9           | 422             | 2427 (45.0)     | 5 (1, 18)       | 893             | 2.0 (0.2, 4.6)  | 1255            | 2.6 (0.6, 25.7) |
| 5–14.9          | 189             | 1147 (21.3)     | 5 (1, 26)       | 606             | 2.2 (0.0, 9.7)  | 578             | 2.7 (0.9, 22.5) |
| 15–17.9         | 61              | 193 (3.6)       | 3 (1, 12)       | 85              | 1.5 (0.2, 2.6)  | 170             | 2.3 (1.3, 10.4) |
| Number of SDE   |                 |                 |                 |                 |                 |                 |                 |
| 1               | 311             | 816 (15.1)      | 2 (1, 12)       | 667             | 0.9 (0.1, 17.6) | 858             | 2.9 (0.2, 27.7) |
| 2–3             | 129             | 231 (4.3)       | 1 (1, 6)        | 165             | 0.3 (0.1, 14.0) | 376             | 3.0 (0.1, 22.5) |
| ≥4              | 33              | 42 (0.8)        | 1 (1, 5)        | 17              | 0.3 (0.3, 2.7)  | 96              | 3.0 (0.8, 4.5)  |
| Daily GC dosea |                 |                 |                 |                 |                 |                 |                 |
| (HC ED mg/ m²/d) |                 |                 |                 |                 |                 |                 |                 |
| Normal          | 423             | 2019 (47.8)     | 4 (1, 24)       | 1224            | 1.8 (0.0, 17.2) | 1508            | 2.7 (0.2, 53.3) |
| High            | 341             | 1201 (28.4)     | 3 (1, 17)       | 763             | 0.7 (0.0, 17.8) | 1762            | 3.0 (0.2, 65.5) |
| Low             | 287             | 1006 (23.8)     | 3 (1, 16)       | 496             | 0.9 (0.1, 17.2) | 999             | 3.0 (0.3, 34.3) |
| Not known       | 282             | 1162 (30.1)     | 3 (1, 20)       | 700             | 1.2 (0.0, 17.6) | 861             | 3.0 (0.1, 30.0) |
| Daily FC dosea |                 |                 |                 |                 |                 |                 |                 |
| (µg/d)          |                 |                 |                 |                 |                 |                 |                 |
| Normal          | 466             | 4374 (90.2)     | 8 (1, 40)       | 1925            | 3.0 (0.1, 17.8) | 1629            | 2.9 (0.2, 45.0) |
| High            | 36              | 111 (2.3)       | 2 (1, 10)       | 23              | 0.3 (0.0, 2.7)  | 372             | 5.4 (1.2, 55.4) |
| Low             | 95              | 359 (7.4)       | 2 (1, 16)       | 160             | 0.9 (0.2, 6.4)  | 283             | 3.0 (0.3, 8.7)  |
| Not known       | 143             | 544             | 2 (1, 23)       | 296             | 0.3 (0.0, 17.6) | 695             | 3.0 (0.3, 65.5) |

GC and FC doses were categorized as low, normal, or high, based on Endocrine Society clinical practice guidance for 21-hydroxylase deficiency CAH (2018)(1) as follows: GC low <10 mg/m²/day, normal 10 to 15 mg/m²/day, high >15 mg/m²/day; FC low <50 µg/day, normal 50-200 µg/day, high >200 µg/day.

Abbreviations: CAH, congenital adrenal hyperplasia; FC, fludrocortisone (µg/day); GC, glucocorticoid; HC ED, hydrocortisone equivalent dose (mg/m²/day); SDE, sick day episodes.

*aFor GC and FC doses, the percentage of total visits was calculated based on “known” (Normal/High/Low) values.*
Risk factors for sick day episodes and adrenal crises

Infectious illness was the most frequent event associated with SDE and AC across all ages, reported in 1105 of 1544 SDE (72%) and in 29 of 62 AC episodes (47%). Surgery was reported as a factor predisposing to SDE in 58 (4%) episodes and no predisposing factor was specified in 381 SDE (24%) and 33 AC (53%). Younger children (aged 1-4 years) and adolescents (15-18 years) had a greater likelihood of a SDE (OR 2.05 [95% CI, 1.63-2.59]; both \( P < 0.001 \), respectively) and an increase in sick day oral GC (OR 2.11 [95% CI, 1.63-2.73]; \( P < 0.001 \) and OR 1.98 [95% CI, 1.57-2.49]; \( P < 0.01 \), respectively) compared with children <1 year of age (Fig. 3). Compared to girls, boys were more likely to have SDE (OR 1.41 [95% CI, 1.14-1.75]; \( P < 0.01 \)) and an increase in sick day oral GC (OR 1.37 [95% CI, 1.08-1.74]; \( P < 0.01 \)). Children receiving lower GC doses (HC ED < 10 mg/m²/day) were more likely to have a SDE (OR 2.00 [95% CI, 1.53-2.63]; \( P < 0.001 \)) and an increase in sick day oral GC (OR 2.27 [95% CI, 1.68-3.08]; \( P < 0.001 \)) than those on higher GC doses (HC ED > 15 mg/m²/day). Similarly, children receiving GC doses within the recommended range (HC ED of 10-15mg/m²/day) were more likely to have SDE (OR 1.47 [95% CI, 1.17-1.85]; \( P < 0.01 \)) and an increase in sick day oral GC (OR 1.73 [95% CI, 1.33-2.24]; \( P < 0.001 \)), than children on higher GC doses (HC ED > 15 mg/m²/day). Due to the small number of AC events overall, which decrease further when broken down by risk factor levels, the multilevel regression model parameters could not be reliably estimated and are not reported.

Management of adverse events

Of the 1544 reports of SDE, there was information on a change in the patient’s usual management documented in 1451 SDE (94%). More specifically, an increase in oral GC dose was noted in 1147 episodes (85%), HC injection was administered in 176 SDE (13%), and information on medical input was available in 1419 SDE (92%) (Fig. 4). A total of 858 SDE (60%) were self-managed in the community and of these, 6 (1%) were associated with an AC. In 561 SDE (40%), medical input, including hospitalization was sought and 55 (10%) of these were associated with an AC. In total, of the 62 episodes of AC that were reported, 55 (90%) were associated with hospitalization. An increase in oral GC or HC injection administration was reported in 52 (84%) episodes of AC; in the remaining 10 (16%) episodes of AC, there was no information regarding an increase in oral GC dose or the administration of HC injection; however, all 10 of these episodes were associated with hospitalization.

Discussion

We report the largest multicenter, international cohort study to date evaluating the epidemiology of acute adrenal insufficiency–related adverse events in children with 21-hydroxylase deficiency CAH. While the majority of studies have measured AC, this is the first study to obtain a more complete perspective on adverse events by measuring SDE, episodes associated with sick day GC doses, and hospitalization in a global cohort of children.

Interestingly, the incidence rate of AC of 2.7 to 3.9 per 100 patient-years is at the lower end of the range that has
Figure 3. Association of age, sex phenotype, and medication dose with sick day episodes (A), an increase in sick day oral GC (B) and hospitalization (C). Abbreviations: FC, fludrocortisone (µg/day); GC, glucocorticoid (hydrocortisone-equivalent dose, mg/m²/day); SW, salt-wasting CAH; SV, simple virilizing CAH. Statistically significant P values are in bold type.
been reported previously (7-10, 25). This is perhaps a reflection of improvements in parent/patient education and increased awareness of AC among families and clinicians. It is also useful to note that overall, less than 5% of SDE were associated with an AC. While it is possible that the management of SDE prevented an AC in these cases, confirmation of a causal link will require further study. Notably, all AC events occurred in children with the salt-wasting phenotype and there were no fatalities. In addition, a lower percentage of SDEs were associated with AC in the 2 decades after 2000 compared to previously; however, these temporal trends may not be reliable, as the data from the older cohort is more likely to suffer from recall bias. Therefore, there is a need to look at temporal trends in more detail and this will become easier to study as regular data reporting is sustained over the longer-term by participating centers.

The SDE incidence rate of 68 per 100 patient-years also deserves attention and further exploration. While controversy remains about the definition of a SDE as well as its appropriate management (16, 26, 27), a change in the patient’s usual medical management, including an increase in oral GC, HC administration, hospitalization, or documentation of a predisposing factor was noted in 94% of SDE. SDE incident rates have not been reported previously; thus, it is unclear as to whether the currently reported SDE rate is particularly high or low. Patients and parents, themselves, may have a different definition of a SDE compared with their clinician and this could be explored in the future by comparing patient/parent reporting to clinician reporting, with the inclusion of more objective criteria for SDE (28).

Infectious illnesses were the commonest event associated with SDE and AC, reported in more than two-thirds of all SDE and almost half of all cases of AC, as reported in previous literature (7-9, 16, 29). The precipitating event in AC was unknown in half of all cases; it is likely that future studies incorporating prospective data collection may facilitate differentiation between specific etiology of infectious illness in children having SDE and AC. More recently, it has been speculated that patients with primary adrenal insufficiency, including CAH, may have a greater predisposition to infections (30) and these associations require further investigation.

Our data show wide variation in the median number of SDEs occurring per patient-year among centers. Moreover, more than half of patients with SDEs were self-managed at home but the majority of those who had an AC were hospitalized. A number of those who were hospitalized did not have an AC reported, thus raising the issue about the

![Figure 4](https://example.com/figure4.png)

**Figure 4.** The management of sick day episodes (n = 1544). (A) Stress dosing, (B) HC injection, (C) AC occurrence, (D) Emergency attendance.

Abbreviations: AC, adrenal crisis; ER, emergency room; HC, hydrocortisone; SDE, sick day episodes.
overlapping definitions of SDE and ACs. In the absence of a clearer distinction between an AC and a SDE, it is possible that hospitalization may be a better definition of a significant adverse event related to adrenal insufficiency. However, it is of course possible that different centers may have a different threshold for “hospitalizing” a patient with an adrenal insufficiency–related adverse event. This threshold for hospitalization may depend on several factors including health care delivery models, health care utilization costs, patient education, as well as the perceived competence of the patient in self-managing their condition (9, 31, 32). In addition, patients from HIC countries had a higher median SDE per patient-year compared with those from LMIC countries. One may expect that patients from LMIC and more deprived communities would have greater SDEs and ACs, due to issues such as reduced access to hospital care and medication. Thus, the factors that influence these results require further evaluation.

The optimal management of children with CAH requires GC regimens that achieve a balance between normal growth and development while avoiding hyperandrogenism and the risk of adverse events associated with adrenal insufficiency (1). Consistent with recommendations from international guidelines, children were reported to be receiving maintenance GC within the recommended range in almost half of clinic visits, with FC doses within recommended dose ranges in 90% of visits. In the current study we observed that the likelihood of SDEs was lowest in those who were on high doses of GC; future studies should also compare the health-economic cost of the morbidity associated with high GC doses against that of adrenal insufficiency–related adverse events. The dose of 10 to 15 mg/m²/day used in children with CAH is greater than that generally recommended for other forms of adrenal insufficiency (33), although there are scarce data on doses of GC used in children apart from in CAH. Furthermore, the majority of patients in our study were very young children and it is recognized that children with CAH may have differing requirements for GC throughout childhood (19); thus, further studies in larger cohorts of children of all ages are required.

A greater likelihood of SDE and sick day dosing was also observed in boys compared with girls. This is contrary to the findings of others where these adverse events were more likely in girls (7, 34). While it is clear that newborn boys with CAH are more likely to present with a salt-wasting crisis when the diagnosis is delayed, it is unclear why boys, or for that matter, girls on maintenance therapy would have a higher incidence of adrenal insufficiency–related adverse events. The majority of studies in adult populations have not revealed a gender difference, although one study reported a higher incidence of adverse events in women with secondary adrenal insufficiency (35) and another reported a greater incidence in men with concomitant hypogonadism (36). Interestingly, children with a salt-wasting phenotype comprised 89% of cases of 21-hydroxylase deficiency in our cohort. This is higher than that previously reported in the literature (2) and may be attributed to several factors including the complex mix of cases being entered by international clinicians, for example, in countries without newborn screening, such as the UK, affected boys may be missed or diagnosed with simple virilizing CAH much later when signs of androgen excess develop, which may perhaps lead to delayed entry into disease-specific registries. The current study also showed that younger (1-4 years) and older (15-18 years) age groups had the greatest risk of SDE. A higher rate of illness episodes in childhood and lower rates of administration of HC injection among very young children have been previously reported as reasons for this observation (7, 16), with young age also consistently recognized as a risk factor for AC (28, 37). These findings may reflect parental uncertainty or inexperience with regards to management of illness episodes in children (38, 39). A higher rate of SDE in adolescents may be attributed to the period of transition from pediatric to adult services, greater patient autonomy, and reduced adherence to therapy (9, 40, 41).

It is possible that this study may experience clinician and patient retrospective recall bias with subjective reporting and a potential for under- or over-reporting of SDE and AC. There may have also been a degree of selection bias, as not every patient at a center had been included in the I-CAH Registry and among those who had been included in this registry, a variable number of cases had a sufficient amount of data to be included in the study. The lack of a universal definition for “sick day episodes” can be considered a limitation. The definition of SDE used herein was based on self-reported physician diagnosis and clinical judgment of the reporting clinician of these events. The current observations highlight the limitation of this definition by not showing any value of SDEs for predicting AC. A combination of the variable criteria for defining SDEs as well as a variable threshold for reporting these adverse events may be an explanation for the observed differences. For instance, the higher prevalence of SDEs in children from HIC could be attributed to greater vigilance and reporting of minor illnesses among parents and clinicians from higher-income countries. Interestingly, there was no difference in the number of AC events between patients from HIC and LMIC, suggesting an equally effective level of illness management and AC prevention. Due to the small number of AC events overall, further studies in a larger cohort of patients with more patient visits and a greater number of ACs are
required to investigate factors that may influence differences in the prevalence of ACs as well as SDEs. A better definition of SDE may be any episode that requires an increase in glucocorticoid replacement above the routine replacement dose, as per local sick day rules and to avoid an adrenal crisis. However, there is a need for further research to achieve a more effective definition of SDE that provides real clinical significance. Furthermore, an online system for collecting patient-reported accounts of SDE and their management may also prove useful in understanding the variation between centers. Lastly, the study did not attempt to assess clinical variables such as the biochemical adequacy of steroid replacement (42, 43). On the other hand, the structured manner of real-world data collection within the I-CAH Registry, the size of the cohort and its potential to represent global practice with the availability of adverse events data for more than half of registered patients under the age of 18 years were clear strengths. Although, the investigators did not have recourse to source data, the data that have been collected have previously been reported to have a high degree of validity, consistency and accuracy (44).

In summary, the real-world data in the I-CAH Registry can be used to identify benchmarks for a range of adrenal insufficiency–related acute adverse events which seem to show clear variation between centers. The current study provides the framework that can be used for studying the effect of targeted interventions that are aimed at improving the care of children with CAH.

Acknowledgments

This work would not be possible without the children and the parents of the children with CAH whose data have been included in the I-CAH Registry. A.T., R.C.C., and I.A.H. acknowledge the support of NIHR Cambridge Biomedical Research Centre. We would like to thank Professor Rodolfo Rey for his advice and would also like to acknowledge the support of the following reference centers that participate in the European Reference Network for Rare Endocrine Conditions (Endo-ERN): the following reference centers that participate in the European assistance and would also like to acknowledge the support of Centre. We would like to thank Professor Rodolfo Rey for his Council (G1100236), the Seventh European Union Framework Program (201444) and the European Society for Paediatric Endocrinology Research Unit. S.R.A. is supported by the Gardiner Lectureship at the University of Glasgow.

Financial Support: The I-CAH Registry was developed using support from an unrestricted education grant from Diurnal Ltd and research grants from the Medical Research Council (G1100236), the Seventh European Union Framework Program (201444) and the European Society for Paediatric Endocrinology Research Unit.

Author Contributions: S.R.A., J.R.R., J.B., and S.E.A. conceptualized and designed the study, designed the data collection instruments, coordinated and supervised data collection, performed the initial analyses, drafted the initial manuscript, and approved the final manuscript as submitted. S.R.A., H.H., S.F.A., and J.D.L. undertook the statistical analyses. All authors contributed to data acquisition, revision of the manuscript, have read and approved the final report and take public responsibility and accountability for the results.

Additional Information

Correspondence and Reprint Requests: Professor S. Faisal Ahmed, MD FRCPCH, Developmental Endocrinology Research Group, School of Medicine, Dentistry & Nursing, University of Glasgow, Royal Hospital for Children, Office Block, 1345 Govan Road, Glasgow G51 4TF, UK. E-mail: Faisal.Ahmed@glasgow.ac.uk.

Disclosure Summary: R.J.M.R. is a Director of Diurnal Ltd.

Data Availability: Some or all datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

References

1. Speiser PW, Arlt W, Auchen RJ, et al. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088.
2. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000;21(3):245-291.
3. Wijaya M, Huamei M, Jun Z, et al. Etiology of primary adrenal insufficiency in children: a 29-year single-center experience. J Pediatr Endocrinol Metab. 2019;32(6):e615-622.
4. Johannsson G, Falorni A, Skrtic S, et al. Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clin Endocrinol (Oxf). 2015;82(1):2-11.
5. Falhammar H, Frisén L, Norrby C, et al. Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2014;99(12):E2715-E2721.
6. Shulman DI, Palmert MR, Kemp SF; Lawson Wilkins Drug and Therapeutics Committee. Adrenal insufficiency: still a cause of morbidity and death in childhood. Pediatrics. 2007;119(2):e484-e494.
7. El-Maouche D, Hargreaves CJ, Sinaii N, Mallappa A, Veeraraghavan P, Merke DP. Longitudinal assessment of illnesses, stress dosing, and illness sequelae in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2018;103(6):2336-2345.
8. Ishii T, Adachi M, Takasawa K, et al. Incidence and characteristics of adrenal crisis in children younger than 7 years with 21-hydroxylase deficiency: a nationwide survey in Japan. Horm Res Paediatr. 2018;89(3):166-171.
9. Rushworth RL, Falhammar H, Munns CF, Maguire AM, Torpy DJ. Hospital admission patterns in children with CAH: admission rates and adrenal crises decline with age. *Int J Endocrinol*. 2016;2016:5748264.

10. Odenwald B, Nennstiel-Ratzel U, Dörr HG, Schmidt H, Wildner M, Bonfig W. Children with classic congenital adrenal hyperplasia experience salt loss and hypoglycemia: evaluation of adrenal crises during the first 6 years of life. *Eur J Endocrinol*. 2016;174(2):177-186.

11. Rushworth RL, Torpy DJ, Falhammar H. Adrenal crisis. *N Engl J Med*. 2019;381(9):852-861.

12. Rushworth RL, Torpy DJ, Stratakis CA, Falhammar H. Adrenal crises in children: perspectives and research directions. *Horm Res Paediatr*. 2018;89(5):341-351.

13. Dineen R, Thompson CJ, Sherlock M. Adrenal crisis: prevention and management in adult patients. *Ther Adv Endocrinol Metab*. 2019;10:2042018819848218.

14. Grossman A, Johannsson G, Quinkler M, Zelissen P. Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. *Eur J Endocrinol*. 2013;169(6):R165-R175.

15. Regan EA, Vaidya A, Margulies PL, Make BJ, Lowe KE, Crapo JD. Primary adrenal insufficiency in the United States: diagnostic error and patient satisfaction with treatment. *Diagnosis (Berl)*. 2019;6(4):343-350.

16. Chrisp GL, Maguire AM, Quartararo M, et al. Variations in the management of acute illness in children with congenital adrenal hyperplasia: An audit of three paediatric hospitals. *Clin Endocrinol (Oxf)*. 2018;89(5):577-585.

17. Dörr HG, Wollmann HA, Hauffa BP, Wölfle J. German Society of Pediatric Endocrinology and Diabetology. Mortality in children with classic congenital adrenal hyperplasia and 21-hydroxylase deficiency (CAH) in Germany. *BMC Endocr Disord*. 2018;18(1):37.

18. Ali SR, Lucas-Herald A, Bryce J, Ahmed SE. The role of international databases in understanding the aetiology and consequences of differences/disorders of sex development. *Int J Mol Sci*. 2019;20(18):4405.

19. Hindmarsh PC. Management of the child with congenital adrenal hyperplasia. *Best Pract Res Clin Endocrinol Metab*. 2009;23(2):193-208.

20. Finkielstain GP, Kim MS, Sinaii N, et al. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. *J Clin Endocrinol Metab*. 2012;97(12):4429-4438.

21. Mosteller RD. Simplified calculation of body-surface area. *N Engl J Med*. 1987;317(17):1098.

22. Paediatric Formulary Committee. British National Formulary for Children (online) London: BMJ Group, Pharmaceutical Press, and RCPCH Publications. [http://www.medicinescomplete.com](http://www.medicinescomplete.com). Accessed February 20, 2020.

23. World Bank Group. World Bank Country and Lending Groups 2020. [https://datahelpdesk.worldbank.org/knowledgebase/articles/906119-world-bank-country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906119-world-bank-country-and-lending-groups). Accessed October 8, 2020.

24. Ali SR, Bryce J, Haghpanah H, et al. Real world estimates of adrenal insufficiency related adverse events in children with congenital adrenal hyperplasia. Glasgow University Enlighten Data Repository. [http://dx.doi.org/10.5525/gla.researchdata.1042](http://dx.doi.org/10.5525/gla.researchdata.1042). Deposited August 4, 2020.

25. Notter A, Jenni S, Christ E. Evaluation of the frequency of adrenal crises and preventive measures in patients with primary and secondary adrenal insufficiency in Switzerland. *Swiss Med Wkly*. 2018;148:w14586.

26. Niranjani U, Natarajan A. Congenital adrenal hyperplasia in children—a survey on the current practice in the UK. *J Pediatr Endocrinol Metab*. 2015;28(7-8):847-851.

27. Riepe FG, Krone N, Viemann M, Parthsj CJ, Sippell WG. Management of congenital adrenal hyperplasia: results of the ESPE questionnaire. *Horm Res*. 2002;58(4):196-205.

28. White K, Arlt W. Adrenal crisis in treated Addison’s disease: a predictable but under-managed event. *Eur J Endocrinol*. 2010;162(1):115-120.

29. Reisch N, Willige M, Kohn D, et al. Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. *Eur J Endocrinol*. 2012;167(1):35-42.

30. Tresoldi AS, Sumilo D, Perrins M, et al. Increased infection risk in Addison’s disease and congenital adrenal hyperplasia. *J Clin Endocrinol Metab*. 2020;105(2):418-429.

31. Jenkins-Jones S, Parviainen L, Porter J, et al. Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia. *Eur J Endocrinol*. 2018;178(4):309-320.

32. Burger-Stritt S, Kardonski P, Pulzer A, Meyer G, Quinkler M, Hahner S. Management of adrenal emergencies in educated patients with adrenal insufficiency-A prospective study. *Clin Endocrinol (Oxf)*. 2018;89(1):22-29.

33. Bornstein SR, Alloizio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2016;101(2):364-389.

34. Rushworth RL, Chrisp GL, Dean B, Falhammar H, Torpy DJ. Hospitalisation in children with adrenal insufficiency and hypopituitarism: is there a differential burden between boys and girls and between age groups? *Horm Res Paediatr*. 2017;88(5):339-346.

35. Hahner S, Loeffler M, Bleicken B, et al. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. *Eur J Endocrinol*. 2010;162(3):597-602.

36. Omori K, Nomura K, Shimizu S, Omori N, Takano K. Risk factors for adrenal crisis in patients with adrenal insufficiency. *Endocr J*. 2003;50(6):745-752.

37. Eyal O, Levin Y, Oren A, et al. Adrenal crises in children with adrenal insufficiency: epidemiology and risk factors. *Eur J Pediatr*. 2019;178(5):731-738.

38. Simpson A, Ross R, Porter J, Dixon S, Whitaker MJ, Hunter A. Adrenal insufficiency in young children: a mixed methods study of parents’ experiences. *J Genet Couns*. 2018;27(6):1447-1458.

39. Fleming L, KnafI K, KnafI G, Van Riper M. Parental management of adrenal crisis in children with congenital adrenal hyperplasia. *J Spec Pediatr Nurs*. 2017;22(4).

40. Gleeson H, Davis J, Jones J, O’Shea E, Clayton PE. The challenge of delivering endocrine care and successful transition to adult services in adolescents with congenital adrenal hyperplasia: experience in a single centre over 18 years. *Clin Endocrinol (Oxf)*. 2013;78(1):23-28.
41. Merke DP, Poppas DP. Management of adolescents with congenital adrenal hyperplasia. Lancet Diabetes Endocrinol. 2013;1(4):341-352.

42. Iwasaku M, Tanaka S, Shinzawa M, Kawakami K. Impact of underlying chronic adrenal insufficiency on clinical course of hospitalized patients with adrenal crisis: A nationwide cohort study. Eur J Intern Med. 2019;64:24-28.

43. Smans LC, Van der Valk ES, Hermus AR, Zelissen PM. Incidence of adrenal crisis in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2016;84(1):17-22.

44. Kourime M, Bryce J, Jiang J, Nixon R, Rodie M, Ahmed SF. An assessment of the quality of the I-DSD and the I-CAH registries - international registries for rare conditions affecting sex development. Orphanet J Rare Dis. 2017;12(1):56.